Restoring Motion: The Rising Momentum of Joint Care Innovation

Viscosupplementation Market Companies Analysis & Forecast 2025–2033

The global viscosupplementation market is entering a phase of consistent and profitable expansion. According to Renub Research, the industry is projected to grow from US$ 4.66 billion in 2024 to US$ 10.16 billion by 2033, reflecting a compound annual growth rate (CAGR) of 9.02% between 2025 and 2033.

This growth trajectory is driven by the rising prevalence of osteoarthritis, increasing aging populations worldwide, growing demand for minimally invasive orthopedic treatments, and continuous advancements in hyaluronic acid (HA) technologies. As healthcare systems emphasize pain management and mobility preservation, viscosupplementation is emerging as a preferred therapeutic alternative before surgical intervention.

Understanding Viscosupplementation and Its Clinical Role

Viscosupplementation is a minimally invasive medical procedure involving the intra-articular injection of exogenous hyaluronic acid (HA) derivatives directly into a patient’s joint—most commonly the knee. Hyaluronic acid is a naturally occurring component of synovial fluid that lubricates joints and acts as a shock absorber.

In patients with osteoarthritis, the concentration and quality of natural synovial fluid decline, leading to increased friction, inflammation, and pain. Viscosupplementation restores the rheological properties of synovial fluid, offering:

·        Improved joint lubrication

·        Reduced inflammation

·        Enhanced shock absorption

·        Pain relief

·        Increased range of motion

Beyond mechanical benefits, HA injections also exhibit chondroprotective and anti-inflammatory properties. The therapy is widely used to treat osteoarthritis of the knee, hip, and hand joints, particularly for patients who do not respond adequately to oral medications or physical therapy.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=viscosupplementation-market-players-analysis-p.php

Market Growth Drivers

Rising Osteoarthritis Prevalence

Osteoarthritis remains one of the most common degenerative joint disorders globally. Sedentary lifestyles, obesity, sports injuries, and aging populations significantly contribute to increasing case numbers. With more individuals seeking non-surgical treatment options, viscosupplementation has gained strong clinical acceptance.

As healthcare providers prioritize joint preservation and early intervention, HA-based injections are becoming part of standardized pain management protocols.

Shift Toward Minimally Invasive Procedures

Patients and physicians increasingly prefer minimally invasive treatments that reduce hospitalization and recovery time. Viscosupplementation fits this model perfectly, offering outpatient administration and low complication rates.

Compared to joint replacement surgeries, HA injections provide a lower-cost alternative for moderate-stage osteoarthritis, delaying or sometimes avoiding surgical procedures altogether.

Innovation in Hyaluronic Acid Formulations

Technological advancements in molecular weight optimization, cross-linking techniques, and multi-injection regimens have enhanced product efficacy. New-generation HA formulations offer longer-lasting pain relief and improved safety profiles.

In January 2024, Zimmer Biomet introduced VISCO3, a three-injection high molecular weight hyaluronate treatment for moderate-stage knee osteoarthritis in select international markets. Clinical trial data demonstrated up to six months of relief and a 52% reduction in pain at 12 weeks.

Competitive Landscape and Leading Companies

The viscosupplementation market features a mix of global pharmaceutical leaders, orthopedic device manufacturers, and specialized biotech firms.

Smith & Nephew PLC

Established in 1856 and headquartered in the United Kingdom, Smith & Nephew develops advanced medical devices for orthopedic reconstruction, sports medicine, and wound care. The company offers hip and knee replacement systems, robotics-assisted solutions, and trauma devices. Its global footprint across Europe, the Americas, and Asia-Pacific positions it strongly within the orthopedic treatment ecosystem.

F. Hoffmann-La Roche Ltd

Founded in 1896 and based in Switzerland, Roche is a biotechnology leader known for its innovative therapies and diagnostics. Through advanced research in autoimmune diseases and musculoskeletal conditions, Roche contributes to expanding therapeutic solutions that complement viscosupplementation.

Sanofi

Established in 1973, Sanofi is a global healthcare company engaged in pharmaceuticals and vaccines. Its strong R&D focus on biologics and precision medicine enhances its strategic relevance in joint and inflammatory disease management markets.

Chugai Pharmaceutical Co.

A subsidiary of Roche, Chugai emphasizes biotechnological research and pharmaceutical innovation. With expertise in immune and bone-related disorders, the company strengthens the broader musculoskeletal treatment segment.

Lifecore Biomedical

Lifecore Biomedical is recognized globally for its expertise in pharmaceutical-grade sodium hyaluronate production. As a contract development and manufacturing organization (CDMO), it supports biotech and pharmaceutical companies from formulation through commercialization, playing a critical role in HA-based therapies.

SWOT Insights of Key Market Participants

LG Life Sciences Ltd

Strength:
Comprehensive R&D and manufacturing capabilities across biologics and specialty pharmaceuticals allow the company to efficiently scale innovative therapies.

Opportunity:
Expansion into emerging markets in Southeast Asia, Latin America, and Africa presents high-growth potential for HA-based injectable therapies.

DePuy Synthes

Strength:
As part of Johnson & Johnson MedTech, DePuy Synthes boasts a broad orthopedic portfolio, including robotic-assisted surgery systems and advanced knee solutions.

Opportunity:
Emerging markets in Asia-Pacific and Latin America offer opportunities for expanded orthopedic and viscosupplementation penetration.

Fidia Farmaceutici S.p.A

Strength:
Fidia is a global leader in hyaluronic acid innovation, holding approximately 1,500 patents, with the majority dedicated to HA production.

Opportunity:
Strategic expansion into high-growth regions and collaboration with healthcare providers can significantly boost global market share.

Recent Industry Developments

·        In March 2025, Anika Therapeutics Inc. strengthened its focus on hyaluronic acid pain relief by divesting Parcus Medical to Medacta Group.

·        In October 2024, Bioventus LLC sold its Advanced Rehabilitation division to Accelmed Partners for US$ 45 million, streamlining its orthopedic portfolio.

·        Ongoing investments in molecular innovation and expanded regulatory approvals continue to intensify competition within the sector.

Market Segmentation Framework

The viscosupplementation market is evaluated across multiple analytical dimensions:

By Product Type:

·        Single-Injection Formulations

·        Multi-Injection Regimens

By Application:

·        Knee Osteoarthritis

·        Hip Osteoarthritis

·        Hand Osteoarthritis

By End User:

·        Hospitals

·        Orthopedic Clinics

·        Ambulatory Surgical Centers

Sustainability and Operational Considerations

Leading companies increasingly incorporate sustainability initiatives into manufacturing processes, including energy-efficient facilities, renewable energy adoption, sustainable packaging materials, and waste reduction strategies.

Corporate strategies also focus on mergers, acquisitions, product benchmarking, pipeline expansion, and geographic diversification to maintain competitive positioning.

Market Outlook and Forecast Analysis

Historical trends show steady demand growth, particularly in developed markets where aging populations dominate. However, emerging economies represent the next frontier, driven by expanding healthcare infrastructure and rising awareness of non-surgical treatments.

With the global market projected to reach US$ 10.16 billion by 2033 at a CAGR of 9.02%, innovation in HA formulations, regulatory approvals, and physician adoption rates will determine future competitive leadership.

Companies covered in detailed analyses include Anika Therapeutics, Zimmer Biomet, Smith & Nephew, Roche, Sanofi, Chugai Pharmaceutical, Lifecore Biomedical, LG Life Sciences, DePuy Synthes, Fidia Farmaceutici, Seikagaku Corp., Ferring Pharmaceuticals, Wellchem Pharmaceuticals, OrthogenRx, and Bioventus.

Final Thoughts

The viscosupplementation market reflects a broader shift in global healthcare—toward minimally invasive, patient-centric treatments that preserve mobility and improve quality of life. With strong projected growth from US$ 4.66 billion in 2024 to US$ 10.16 billion by 2033, the sector stands at the intersection of biotechnology innovation and orthopedic care evolution.

As research advances and patient demand for non-surgical options increases, viscosupplementation is positioned not merely as a temporary relief measure but as a strategic pillar in osteoarthritis management. Companies that prioritize innovation, geographic expansion, and sustainable production will define the next chapter of growth in this dynamic and expanding market.